Summarize the established knowledge on this subject

• Registry studies show that patients with advanced stages of liver disease are at risk of mortality caused by COVID-19. But since data is entered by the treating physicians, there may be a bias towards reporting severe cases.

• Limited data is available on COVID-19 in patients with autoimmune liver disease (AILD). Immunosuppressive treatment required in patients with AIH and AILD patients after liver transplantation might represent an additional risk factor.

What are the significant and/or new findings of this study?

• In our patient-oriented survey we did not detect a higher frequency of COVID-19 cases in patients with AILD compared to the general population.

• These results suggest that patients with AILD are not at elevated risk of COVID-19. Our study is therefore an important addition to existing registry studies evaluating the risk of COVID-19 in patients with AILD.